XML 24 R19.htm IDEA: XBRL DOCUMENT v2.3.0.15
Significant Accounting Policies (Details 3) (USD $)
3 Months Ended9 Months Ended12 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Sep. 30, 2011
Y
D
entity
count
Sep. 30, 2010
Dec. 31, 2010
entity
Consolidation of variable interest entities     
Number of variable interest entities in which the entity is not primary beneficiary  8 8
Comprehensive loss:     
Unrealized holding gains (losses)$ (1,552,000)$ 221,000$ (2,102,000)$ (66,000) 
Reclassification adjustment for realized loss included in net loss   (925,000) 
Net loss(26,882,000)(12,454,000)(64,765,000)(47,265,000) 
Comprehensive loss(28,434,000)(12,233,000)(66,867,000)(48,256,000) 
Convertible debt     
Interest rate on convertible debt (as a percent)2.625% 2.625%  
Regulus Therapeutics Inc.
     
Equity method of accounting     
Principal plus accrued interest guaranteed on Regulus convertible notes$ 5,400,000 $ 5,400,000